Titan Pharmaceuticals, TTNP, Profile

Titan Pharmaceuticals, TTNP, is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders.

Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations.

The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes.

Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Sources: company, OxBridge Research, Daily Stock Deals

Fuse Science, DROP, Profile, Summary

Fuse Science (DROP) is a consumer products company, developed an alternative delivery systems with applications in the sports nutrition and medical fields. Its delivery systems include sublingual and transdermal delivery technologies that enable energy, medicines, vitamins, and minerals to bypass the gastrointestinal tract and enter the blood stream directly.

The company offers EnerJel to address muscle fatigue and soreness, before, during, and after physical activity. It also provides drop products, including PowerFuse, an energy formulation in a concentrated drop, as well as ElectroFuse, an electrolyte formula in a concentrated drop.

Fuse focus provides revolutionary energy and body replenishment products that combine cutting-edge body delivery technology with two proprietary formulas for powering professional athletes and weekend warriors. Utilizing our unique, bonding technology, Fuse Science has a unique electrolyte and energy delivery system for consumers ranging from the serious athletes to working mothers.

A combination of patent pending technology and unique ingredients has resulted in achievement of superior cosemtic, consumable, transdermal and sublinguall delivery of nutraceuticals and pharmaceuticals. This unique delivery system has allowed for increased absorption of encapsulated nutrients across the epidermis and oral mucosa in our transdermal and sublingual formulations.

ENERJEL™
Innovative Topical Muscle & Joint Rub from Fuse Science

ENERJEL™ is Fuse Science Inc.’s first innovative, topical product which utilizes elements of their cutting edge delivery system. The proprietary formulation helps fatigued muscles feel energized. ENERJEL™ is applied topically to deliver sustained relief and an energized feeling.

• ENERJEL’s™ proprietary formulation helps fatigued muscles feel energized.

• Powered By Fuse™ and made from all natural ingredients, ENERJEL™ is applied topically to help deliver a sustained energized feeling to the target area.

• ENERJEL™ contains all natural ingredients, such as white willow bark and caffeine

Sources: company, OxBridge Research, Daily Stock Deals

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

MAKO Surgical (MAKO), a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally.

The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.

In addition, the company offers MAKOplasty partial knee arthroplasty (PKA) products that enable resurfacing of one or two specific diseased compartments of the joint, preserving more soft tissue and healthy bone of the knee; and MAKOplasty Total Hip Arthroplasty, a surgical solution that enables orthopedic surgeons to perform total hip arthroplasty.

Further, it provides RESTORIS onlay knee implant system for patients who lack tibia sclerotic bone beds; RESTORIS MCK unicompartmental and bicompartmental knee implant system to support the tissue and bone sparing goals of MAKOplasty PKA; and RESTORIS family of hip implant systems.

The company markets and sells its products through direct sales force, as well as through independent orthopedic product agents and distributors. MAKO Surgical Corp. was founded in 2004 and is headquartered in Fort Lauderdale, Florida.

Sources: company, OxBridge Research, Daily Stock Deals

Prospect Global Completes Senior Debt Restructuring

DENVER, April 16, 2013 /PRNewswire/ -- Prospect Global Resources, Inc. (PGRX) announced today the successful restructuring of its long-term debt with the Karlsson Group ("KG"), advancing its long-term plan to build a potash mine in the Holbrook Basin of Arizona.

Key highlights include:

• Debt maturity extended to July 2015; interim principal payment of $30 million due January 2015

• Interim payments to KG decreased to 10% of any capital raised after $10 million of capital raised (previously 40% of any capital raised)

• Restructured $6.75 million Unsecured Notes from 3^rd party to extend maturity dates, and reduced interim capital payments to 10% of any capital raised after $10 million of capital raised (previously 33% of any capital raised)

• The Company is required to meet interim financing milestones to fund the continued development of the Holbrook Basin project

"We are very pleased with the outcome of our restructuring efforts," said Damon Barber, Prospect Global's President and Chief Executive Officer. "The restructuring of our debt marks a significant step forward for the company. Despite the recent volatility in our stock price, we believe that we are now well positioned to move forward in building long-term value for all shareholders."

About Prospect Global Resources, Inc.

Prospect Global Resources, Inc. is a Denver-based company engaged in the exploration and development of a large, high-quality potash deposit located in the Holbrook Basin of eastern Arizona. The company's stock is traded on the NASDAQ Stock Exchange under the ticker symbol PGRX.

Additional details about Prospect Global Resources Inc. can be viewed at the Company's website, www.prospectgri.com.

Kimber, KBX, owns mineral concessions covering in excess of 39,000 hectares in the prospective Sierra Madre gold-silver belt, including the Monterde property, where three gold-silver mineral resources have already been defined. The most advanced of these, the Carmen deposit, has been extensively drilled and has undergone detailed geologic modeling. The completion of the Updated Preliminary Economic Assessment for Monterde in 2011 represented a significant step forward for Kimber and supported further evaluation and more advanced economic studies at the Monterde deposits, with the recently filed 2012 Updated Mineral Resource Estimate Technical Report for the Carmen deposit representing a component of those activities.

Source:company, OxBridge Research, Daily Stock Deals